
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Calpain 6 CRISPR Activation Plasmid (h) | sc-407700-ACT | 20 µg | $397.00 |
Human CAPN6 encodes calpain 6, an atypical calpain family member with limited or absent protease activity that functions primarily as a regulator of cytoskeletal organization. Calpain 6 is linked to microtubule stabilization, cell shape control, and modulation of cell motility and adhesion, processes that intersect with pathways governing differentiation and tissue remodeling. CAPN6 expression is frequently studied in contexts of developmental programs and cellular stress responses where changes in cytoskeletal dynamics impact proliferative and migratory phenotypes. Dysregulated CAPN6 has been reported in multiple disease-associated transcriptomic signatures, supporting its use as a mechanistic node for investigating cytoskeleton-dependent remodeling and aberrant growth states.
Calpain 6 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CAPN6 expression without altering the underlying DNA sequence.
Calpain 6 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CAPN6 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CAPN6 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Calpain 6 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CAPN6 locus and enabling the study of Calpain 6-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Calpain 6 pathway restoration in tumor cells with silenced or reduced CAPN6 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.